Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1336-1339

  Wintergerst, U ^a   Hoffmann, F ^a   Jansson, A ^a   Notheis, G ^a   Huss K ^a   Kurowski, M ^b   Burger, D ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HIV Laboratory Therapia GmbH   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Non nucleoside reverse transcriptase inhibitor; Paediatrics; Therapeutic drug monitoring

Indexed keywords

EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIVIRAL ACTIVITY; ARTICLE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILD CARE; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION RESPONSE; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOSIS; SEIZURE; SIDE EFFECT; SLEEP DISORDER; VIRUS LOAD;

ADOLESCENT; AGE FACTORS; ANTI-HIV AGENTS; ATTENTION; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DYSSOMNIAS; HIV INFECTIONS; HIV-1; HUMANS; METABOLIC CLEARANCE RATE; PLASMA; PSYCHOTIC DISORDERS; SEIZURES; TREATMENT OUTCOME; TREATMENT REFUSAL; VIRAL LOAD;

EID: 44449117374     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn112     Document Type: Article

References (17)

1. European Medicines Evaluation Agency. Sustiva; Summary of Product Characteristics, 2 February 2007. http://www.emea.europa.eu/ (26 January 2008, date last accessed).
2. Food and Drug Administration. Sustiva; Prescribing information, 24 January 2007. http://www.fda.gov (26 January 2008, date last accessed).
3. Starr SE, Fletcher CV, Spector SA et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse- transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Enql J Med 1999; 341: 1874-81.
4. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection; 26 October 2006. http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf (22 February 2008, data last accessed).
5. Sharland M, Blanche S, Castelli G et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5 Suppl 2: 61-86.
6. Teglas J, Quartier P, Treluyer J et al. Tolerance of efavirenz in children. AIDS 2001; 15: 241-3.
7. Funk MB, Notheis G, Schuster T et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Eur J Med Res 2005; 10: 503-8.
8. von Hentig N, Koenigs C, Elanjikal S et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res 2006; 11 377-80.
9. Scherpbier HJ, Bekker V, Pajkrt D et al. Once-daily highly active antiretroviral therapy for HIV-infected children: Safety and efficacy of an efavirenz-containing regimen. Pediatrics 2007; 119: e705-e715.
10. Ren Y, Nuttall JJ, Egbers C et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr 2007, 45: 133-6.
11. La Porte CJL, Back DJ, Blaschke T et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006; 3: 4-14.
12. Engelhorn C, Hoffmann F, Notheis G et al. Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children. Eur J Med Res 2002; 7: 30-4.
13. Judd A, Doerholt K, Tookey PA et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: Planning for teenage and adult care. Clin Infect Dis 2007; 45: 918-24.
14. McKinney RE, Jr, Rodman J, Hu C et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 2007; 120: E416-23.
15. Burger D, Van der Heiden I, laPorte C et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61: 148-54.
16. Saitoh A, Fletcher CV, Brundage R et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 2007; 45 280-5.
17. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.